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Prospective Evaluation of 2-[l8F1-2-Deoxy-D-Glucose Positron
Emission Tomography in Staging of Regional Lymph Nodes
in Patients With Cutaneous Malignant Melanoma
By David J. Macfarlane, Vernon Sondak, Timothy Johnson, and Richard L. Wahl
Purpose: To assess prospectively the accuracy of
2-[' 8F]-2-deoxy-D-glucose positron emission tomogra-
phy (FDG-PET) for predicting regional node involvement
in cutaneous malignant melanoma (CMM).
Patients and Methods: Twenty-three patients with
CMM (primary lesions > 1.5 mm thick) scheduled for
lymph node dissection (LND) were preoperatively stud-
ied with FDG-PET. Thirteen patients underwent therapeu-
tic LND of 14 node basins, while nine patients had
elective LND of 10 node basins. Medical problems pre-
cluded surgery in one patient. Two observers unaware
of the clinical node status-apart from whether a recent
surgical scar was present-read attenuation-corrected
reconstructed transverse images acquired between 50
and 60 minutes after injection. Intensity of FDG uptake
was scored as 0 to 3 + on a semiquantitative four-point
scale: 0, no uptake; 1 +, faint; 2 +, moderate; and 3 +,
intense uptake. A node group was considered positive
on FDG-PET if it contained at least one focus of FDG
THE INCIDENCE OF cutaneous malignant melanoma
(CMM) has risen twofold to threefold over the last 35
years, with predictions that one in 90 Amencans will
develop a melanoma by the year 2000.1,2 There is no
satisfactory treatment for disseminated disease. Complete
excision of the primary tumor in the early stages and,
occasionally, resecting an isolated regional lymph node
metastasis (lymph node dissection [LND]) provides the only
chance for certain cure. The traditional model of melanoma
progression consists of discrete steps, which commence with
horizontal spread of the pnmary lesion, followed by a
vertical growth phase with increasing invasive potential,
local spread, including extension to regional lymph nodes,
and finally, hematogenous dissemination.' The detection of
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uptake of - 2+ intensity. Histopathologic examination
of the 24 dissected node groups served as a reference.
Results: Considering regional node basins, PET imag-
ing demonstrated 11 true-positive (TP), 10 true-nega-
tive (TN), two false-negative (FN), and one false-
positive (FP) result, for an overall accuracy of 88%.
Histopathologic from one FN case showed seven malig-
nant cells in a marginal node sinus. The FP was due to
reactive changes postbiopsy. In one patient, clinically
involved lymph nodes were correctly categorized TN by
PET. At least four additional 2 + foci seen outside the
dissected regions on PET may represent metastases and
are being monitored.
Conclusion: FDG-PET accurately predicted regional
node status in 88% of CMM cases. The failure to detect
micrometastatic disease may be due to the limitations of
the imaging equipment and technique used here.
J Clin Oncol 16:1770-1776. o 1998 by American
Society of Clinical Oncology.
circulating tumor cells in patients with apparently isolated
cutaneous primary lesions suggests that the actual process is
more complex and less well demarcated than this schema
suggests.3 Primary tumor thickness (Breslow thickness) is
the primary determinant of prognosis and is strongly corre-
lated with an increasing rate of nodal and systemic involve-
ment.4. 5 With the development of regional lymph node
metatases, both the number of individual nodes involved and
total nodal tumor burden provide further prognostic informa-
tion.6
Elective LND (ELND) and therapeutic LND (TLND)
have formed sometimes controversial components of treat-
ment strategies for CMM 5-12 Depending on operative tech-
nique and site, LND is associated with complications in 5%
to 40% of cases, most prominently lymphedema, with
infection less common 9 Optimally, node dissection would
be considered only in patients with documented nodal
disease, rather than the blanket approach currently pursued
in elective dissection, which reflects the insensitivity of
current techniques to detect small metastases. All node
dissections would therefore be therapeutic, albeit with
different intent. In those patients with small nodal tumor
burdens and a hopefully small chance of more distant
spread, the procedure may be curative. If the nodal involve-
ment is detectable cnically, the chance of cure is reduced,
and dissection is performed in this case largely to provide
palliation of local tumor mass effects (the traditional TLND).
Journal of Clinical Oncology, Vol 16, No 5 (May), 1998. pp 1770-17761770
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PROSPECTIVE FDG-PET IN MALIGNANT MELANOMA
Recently, treatment with interferon has been shown to
improve survival in patients with lymph node involvement.
The appropriate regional node group for dissection may be
difficult to identify, as it is ambiguous or multiple in 57% of
patients with primary melanoma of the head, neck, or trunk
who undergo lymphosclntigraphy."1 This means that more
than one lymph node group would require dissection.
Clinical examination and anatomic imaging techniques
are suboptimal techniques for assessing disease extent. 9,1Oi3
A recent pilot study documented avid uptake of 2-[18F]-2-
deoxy-D-glucose (FDG) on positron emission tomography
Fig 1. True-positive study. Representative delayed transaxial FDG-PET
images of the inguinal region from patient 3, which show intense tracer
accumulation (white area) in the involved left node group.
Fig 2. True-negative study. Delayed transaxial FDG-PET images of the axillae
in patient 9, with the only significant FDG activity within the mediastinum.
(Note that no "white areas" are identified.) All nodes were free of tumor at
surgery.
Fig 3. False-negative study. Transaxial images from patient 7, which
demonstrate a moderately intense focus of FDG accumulation within the L
axilla (SUV, = 2.1), in a study marred by motion artefact. This study was
read as negative, although 1 of 17 dissected lymph nodes contained
melanoma.
(PET) imaging by nearly all untreated melanoma deposits
within lymph nodes and viscera. 4 Using serial transmission
computed tomography (CT) and biopsy findings for confir-
mation, PET correctly identified 15 of 15 visceral and
intraabdominal lymph node metastases that ranged between
0.5 and 8 cm in diameter. Eight additional foci of intensely
increased FDG uptake were evident for which the presence
of tumor had not yet been confirmed or excluded. Metastatic
involvement was correctly identified in seven of seven
tumor-involved node groups, including foci detected within
three lymph node groups that were normal by clinical and
CT criteria. Conversely, PET correctly predicted lack of
tumor involvement in six of six lymph node regions,
including two enlarged nodes of 1.5 to 2.0 cm in size for
which pathologic confirmation was obtained.
Although sensitivity and specificity were 100% for those
lymph node deposits for which anatomic correlation was
possible, this was not available for all nodal sites. It was also
not established by the pilot study whether metastatic involve-
ment could be reliably distinguished from other inflamma-
tory or infectious processes. To address these questions, we
prospectively studied with FDG-PET the regional node
basins of patients with CMM scheduled for ELND or TLND
and compared the results of noninvasive PET scanning with
pathology of the lymph nodes excised at surgery.
PATIENTS AND METHODS
FDG Production
Fluonne 18 was produced by acceleration of deuterons into an
oxygen-18-water target, and high-speclfic-activity FDG subsequently
produced by nucleophilic fluonnation. Thin-layer chromatography was
performed to assess purity. Methods of production were in accord with
those for an investigational new drug registered with the United States
Food and Drug Admumstration.
Patient Population
Patients ehgible for enrollment were adults attending the Umversity
of Michigan Melanoma Clmic with CMM of primary lesion thiuck-
ness - 1 5 mm scheduled for ELND and those with clinical, sometimes
cytopathologically proven, nodal involvement for palliative therapeutic
dissection regardless of the primary lesion thickness. Pregnant and
lactatmg patients were excluded, as were those who had received
chemotherapy or radiotherapy before enrollment Evidence of active
local or systemic infection, or history of another malignancy, were also
cntena for exclusion. Twenty-three patients (18 men and five women)
were studied The study protocol was approved by the Insitutonal
Review Board at the University of Michigan. All patients provided
written informed consent before scanng. Node dissection was per-
formed 1 to 18 days after PET imaging. The prospective protocol
dictated that the surgeon not be informed preoperatively of the
FDG-PET scan result unless it suggested the presence of soft tissue
metastases Patient details are listed m Table 1.
PET Scanning
Patients were scanned using either Siemens-CTI model 921 or 931
ECAT scanners (Siemens Medical Systems, Iselin, NJ; CTI, Knoxville,
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Table 1. Summary of Patient Data
Patient Primary Lesion Site ELND/ Level SUV In Operative
No (thickness, site) Dlssected TLND Scanned Abnormalty Score (maximum) Field? Pathology
1 3 7, R neck R neck ELND Head, neck Nil 0 Yes 38 -ve LN
L neck ( mastoid) 2+ No
2 2 5, L neck L neck ELND Head, neck Nil 0 Yes 13 -ve LN
R maxillary sinus 1+ No
3 3.3, L calf L groin TLND Thigh, pelvis Multiple 3+ Yes 6 of 17 LN +ve
4 3.3, Lcalf Lgroin TLND Thigh, pelvis Multiple foci Lgroin 3+ 5.37 Yes 2of5 LN +ve
Multiple foci R groin 2+ 1.76 No
5 1 1,Ant abd wall Lgroin TLND Thigh, pelvis 2 foci L groin 3+ 71 Yes 4of 16 LN +ve
6 4 4, L tragus L neck ELND Head, neck Nil 0 Yes All LN -ve
7 L upper arm L axilla TLND Neck, axilla Single focus L axilla 1 + 2 08 Yes 1 of 17 LN +ve
8 3 5, L occiput Post neck TLND Neck Nil 0 Yes All LN -ve
9 Thick, R 4th digit R axilla TLND Axilla Nil 0 Yes All LN -ve
10 3.6, nape neck Bllat neck ELND Neck, axilla Nil 0 Yes 24 -ve LN
11 2.1, R cheek R neck ELND Neck Nil 0 Yes 1 of 7 LN +ve
12 1 6, tip Rear Rneck TLND Neck 3 foci R neck 3+ 5.2 Yes 4 of 44 LN +ve
13 2, abdominal wall R groin TLND Pelvis, thigh Small focus R groin (scar) 3+ Yes 15 -ve LN
Single focus L groin 1 + No
14 3 3, R neck R neck ELND Neck, axilla Nil 0 Yes 22 -ve LN
15 1.7, posterior Lear L neck ELND Neck, axilla L ear 1+ 1 82 Yes All LN -ve
R axilla 2+ 1.86 No
16 3.2, sternal notch L neck TLND Neck, axilla Ant L neck 3+ 2 93 Yes 1 of 16 LN +ve
R axilla 3+ 2 43 No
L axilla 1 + No
17 1 0, sternal notch R neck TLND Neck, axilla R acromioclovicular joint 3+ No A-C joint arthritis
18 2.3, R neck R neck TLND Neck, axilla R neck below ear 3+ 2.85 Yes Parotid LN +ve
19 2 1, Larm Laxilla TLND Neck, axilla Single focus L axilla 3+ Yes 1 of 24 LN +ve
20 Unknown, R neck Neck ELND Neck Nil 0 Yes 31 -ve LN
21 8 0, midline back R, L axillae TLND Neck, axillae Single focus Laxilla 3+ Yes 1 of 17 LN +ve
Single focus R axilla 3+ Yes 1 of 25 LN +ve
22 2.3, L arm L axilla ELND L axilla Nil 0 Yes All LN -ve
Abbreviations: R, right, L, left, -ve, negative, +ve, positive; LN, lymph node
TN). All patients fasted for at least 4 hours before scanning. Patients
underwent transmission scanning with a germanium-68/galhum-68 nng
source at one or two levels encompassing the node groups planned for
dissection. Immediately before intravenous administration of 10 mCi of
FDG, tracer was injected where possible into the limb contralateral to
and remote from the proposed site of dissection.
Dynamic images were acquired through 60 minutes postinjection at a
level that included the nodal basin to be dissected and if possible, the
site of the primary lesion. This sequence comprised 5 X -mnute
frames and 1 X 5-munutes frame, followed by frames of 10 minutes
duration to 60 minutes postinjection. In 17 patients, a further 10-mmnute
static image was acquired between 60 and 70 minutes postinjection at a
level contiguous with the imtlal acquisition, selected to include alter-
native sites of tumor spread (eg, axillae in the case of a head and neck
primary tumor). In the remaining three patients, four or five levels were
scanned in whole-body mode following scanning of the first level.' 5
Qualitative and quantitative interpretation of images were based on the
50- to 60- and 60- to 70-mnute images Images were reconstructed into
a 128 x 128 matrix using a filtered back-proJection algorithm and
attenuation corrected with the initial transmission data. Serum glucose
levels before and after each scan were unremarkable m all patients.
Image Interpretation
The reconstructed images were independently assessed on a dedi-
cated digital image display system by two experienced reviewers
(R L.W. and D.J.M.) Studies were provisionally reviewed without
clinical information being provided to the interpreting physicians other
than the timing and site of any biopsy or excision performed in the area
of interest
Studies were initially assessed for technical adequacy, particularly
freedom from motion artifact. For each patient, observers scored the
visual intensity of FDG uptake within the node basin on the 50- to 60-
and 60- to 70-minute images using a semiquantitative four-point scale.
Review of early dynamic frames was used to help identify vascular
structures. A score of 0 represented FDG uptake clearly less than
vascular background, 1 +, questionable increase; 2 +, moderate in-
crease, and 3 +, definitely increased uptake relative to blood activity
Individual observer scores were compared and a consensus reading
reached in cases of disagreement. To permit binary analysis of data,
node basins that contained areas of uptake with a score > 2+ were
considered to be involved by tumor and those with foci of a maximum
intensity of 0 or 1 + were classified as uninvolved by tumor. Increased
uptake of FDG at recent operative sites and m actively healing tissues is
a known potential pitfall in interpretation of FDG-PET studies. Interpre-
tation of these foci without knowing whether a recent surgical
procedure had been performed would potentially lead to false-positive
(FP) interpretation. Foci of FDG uptake corresponding to healing recent
surgical scars were therefore considered not to represent tumor. On
clinical grounds, it was not possible to defer PET imaging (and
therefore) or surgery until any such scars had healed. Where possible,
maximum and mean standardized uptake values (SUV) were estimated
for lesions using a previously descnbed technique, with no correction
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tor count recovery coefficient 16 17 Scan reports were only provided to
the operating surgeon if remote disease was identified, and were not
otherwise used to plan the surgical procedure
Surgical and Pathologlc Assessment
Dissection of regional node groups was performed under general
anesthetic by surgeons experienced in the procedure and consisted of
extensive nodal clearances In most cases Pathology staff were aware of
the study, but participating patients were not individually identified to
them Study specimens were examined and reported along with routine
clinical maternal The number of lymph nodes contained wlthm the
surgical specimen was determined, and each node then sectioned and
examined for the presence of tumor using routine hlstopathologlc
techniques, which included mmunohlstochemlstry m selected in-
stances
RESULTS
A total of 23 patients (18 men and five women) entered
the study and underwent FDG-PET scanning, with 22
proceeding to node dissection. Intercurrent medical prob-
lems at the time of surgery precluded node dissection in one
patient, who is not considered in our analysis. A total of 24
node basins were dissected in the 22 patients, with ELND
performed in nine patients (10 node basins) and dissection of
clinically enlarged nodes In the remaining 13 (14 node
basins). Bilateral neck dissection was performed in patient
no. 10, and bilateral axlllary dissections in patient no. 21
The axilla was dissected in seven patients and the ingumnal
region in four, with the remaining patients undergoing neck
dissection. In elective dissections, the extent of surgery was
guided by usual regional drainage patterns, supplemented in
several cases by colloid lymphoscmtigraphy if regional
lymphatic drainage was potentially ambiguous. Ten of the
24 node groups were positive for tumor by FDG-PET
criteria. Metastatic melanoma was found in each PET-
positive patient, all of whom were scheduled for dissection
of clinically abnormal lymph nodes In three patients, FDG
uptake of - 2+ intensity was seen superficially at the site of
dissection; In these cases, recent blopsles had been per-
formed in the region and the abnormal uptake correctly
attributed to this, as there was no underlying tumor evident
at surgery.
The absence of tumor was confirmed histopathologlcally
in 10 of the 11 node groups with negative FDG-PET studies.
The two remaining negative studies were charactensed as
false-negative (FN) results. In patient no. 11, a mlcrometas-
tasls of approximately seven tumor cells was present within
the marginal sinus of one node. In the other such study
(patient no. 7), one of 14 nodes contained tumor, although,
unfortunately, metastasis dimensions were not determined
for this subject. A faint (I + intensity) focus of FDG uptake
was evident on the scan with a maximum SUV of 2 1,
compared with values of 2.9 to 7.1 for the other confirmed
tumor deposits. The technical quality of this study was
marred by patient motion.
Patient no. 9 underwent an axilllary node dissection on the
basis of clinical lymphadenopathy. FDG-PET correctly
predicted the absence of tumor in the node group. Consider-
ing node basins for ELND and TLND together, the sensitiv-
ity and specificity of FDG-PET m the detection of tumor
were 85% and 92%, respectively. Twenty-one of 24 node
groups (88%) were therefore correctly characterized nonin-
vasively by PET.
Of nine patients (10 node basins) who underwent ELND,
nine basins were categorized as true-negative (TN) and one
as FN. For the TLND dissection group, of 13 patients (14
basins), there were 11 TP, one TN, and one FN. The
markedly different tumor incidence reflects the low likeh-
hood of metastatic disease in the group selected for ELND.
Four foci of 2 + intensity or above were seen m node
basins imaged but not dissected. One patient with this
finding subsequently developed a palpable axillary node,
with neoplastic involvement confirmed by aspiration biopsy.
The other patients are still being monitored. No adverse
effects were reported from the FDG-PET studies.
DISCUSSION
FDG-PET is a promising tool in the initial staging and
assessment of response to therapy for a range of tumors.
Melanoma is among these, as it exhibits intense uptake and
marked retention of FDG in both animal models and
humans, which is decreased by the administration of some
chemotherapeutic agents. 4,18 Gritters et al14 described nine
cases in which FDG-PET correctly predicted the presence
(three patients) or absence (six patients) of metastatic
melanoma within clinically normal lymph nodes. Clinical
assessment of lymph node involvement by tumor may be
inaccurate In a variety of malignancies, 6% to 21% of
lymph nodes were judged to be clinically involved without
subsequent histologic evidence of malignancy, while in 21%
to 55%, the reverse was found to be the case, with the actual
percentages dependent also on site and series.9 0
The elective resection of clinically uninvolved regional
nodes with an isolated primary lesion on the premise that
unresected nodal micrometastases may compromise survival
has been a contentious issue. It is generally accepted that the
infrequent nodal involvement with thin (< 1.50 mm) pri-
mary lesions does not justify ELND.7 8 This is least contro-
versial when multiple potential paths of lymphatic drainage
are identified at lymphoscintigraphy. In retrospective series,
the overall yield of positive nodes from ELND ranges from
16% to 55% of cases and increases with primary lesion
thickness. The available literature suggests that the proce-
dure confers little, if any, survival advantage. 5,7,10 12 How-
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ever, a substantial amount of the data that form the basis for
this conclusion are retrospective and subject to criticism.
The results of the prospective Intergroup Melanoma Commit-
tee trial are yet to be formally released at the time of writing,
but preliminary indications suggest that these will be
similar.5 It is generally accepted that clinically involved
nodes be dissected as a palliative measure irrespective of
primary lesion thickness.' Obviously, noninvasive determi-
nation of tumor presence or absence would be useful in
planning management. Successful treatment of regionally
metastatic melanoma with interferon has increased the
importance of diagnosis of nodal metastases.
The prevailing perceived lack of benefit of ELND is a
major factor behind the preponderance of patients with
climcally involved nodes for palliative resection in the study
population. Patients for ELND with primary lesion thick-
ness < 1.5 mm (Breslow thickness) were ineligible for
enrolment in view of the low probability of nodal involve-
ment. FDG-PET correctly indicated the presence or absence
of tumor in all patients scheduled for TLND. Tumor was
present in only one of the nine node groups for ELND
evaluated in this study, a proportion less than expected from
the previous literature. This may be due to the small sample
size, but may also be partly attributable to changing criteria
for patients to undergo ELND.
In one case, the tumor burden consisted of only a few
cells, unable to be resolved by FDG-PET, and m fairness, not
by any other current in vivo diagnostic modality. The other
FN study, in the TLND group, was of suboptimal technical
quality due to patient motion, but not judged sufficiently so
as to warrant exclusion from formal analysis. The single
false-positive (FP) result was due to a reactive lymphadeni-
tis. Absolute hlstopathologic dimensions of the nodal tumor
burden were unavailable, the lesion being described as small
in the histopathology report. In retrospect, the Intensity of
FDG uptake by the lesion was probably graded conserva-
tively.
Although the numbers are small, these new cases taken
together with the work of Gritters et al14 suggest that
FDG-PET will detect most macroscopic nodal melanoma
metastases, although some very small lesions will not be
detected. The high sensitivity and specificity for tumor
detection is reassuring, although in the TLND group clinical
examination yielded comparable sensitivity. However, PET
exhibited superior specificity, showing no tumor in the three
node basins in this group with clinically enlarged nodes but
reactive change only on pathologic examination. When
combined with the prospective study by Gritters et al, 34 of
37 lymph node groups were correctly characterized by PET
according to the presence or absence of tumor, with an
accuracy of 92%. It should be noted that neither of the PET
scanners used in this series was a state-of-the-art instrument.
The potential of FDG-PET to detect occult nodal metasta-
ses was first demonstrated m animal tumor models and
subsequently in women with breast cancer.'9-2 1 From exami-
nation of 199 cervical nodes dissected from 12 patients,
Braams et a122 recently concluded that FDG-PET was more
sensitive than either magnetic resonance imaging (MRI) or
clinical examination for detection of cervical nodal metasta-
ses from oropharyngeal squamous cell carcinomas, with a
sensitivity of 91% and specificity of 88%. The technique by
which individual nodes were identified across the three
techniques is not clear, with image registration apparently
not being used. Although the imaging characteristics of each
lymph node were treated as being completely independent
variables in the accompanying analysis, this approach may
not be appropriate, since it is likely that at least some of the
tumor sites within a given patient will exhibit similar
biologic characteristics. Overall, in these studies, the sensi-
tvity of PET for detecting a wide range of neoplastic lesions
was greater than 90%.
In a similar, although smaller series, Jabour et a 23
reported a sensitivity of 73.5% and specificity of 99% for
FDG-PET in head and neck cancer staging. The clinical state
of the nodes was not stated, nor was interpretation of the
FDG-PET undertaken independently of the MRI results. The
sensitivity of FDG-PET for small tumors could almost
certainly be enhanced through the use of higher resolution
PET scanners than used in this study. PET has been shown to
be more accurate than CT for staging nodal metastases of
non-small-cell bronchogemc carcinoma as well.
Reactive change within lymph nodes and inflammation
within other soft tissues may exhibit increased FDG uptake
with SUVs not significantly different from those seen in
metastatic involvement, constituting a potential source of FP
results. Indeed, Boni et al reported FP results m two patients
with wound infections. To maintain the specificity for tumor,
it is important that, if possible, FDG-PET scanning not be
performed soon after surgery on the region in question, and
that image interpretation be made with full knowledge of the
site, timing, and extent of any such interventions. Attributing
FDG uptake to wounds or inflammation rather than tumor
was justified on the basis that (1) active healing is associated
with increased FDG uptake even in the absence of residual
tumor; (2) histopathology of the resections showed the
excised specimen to have clear margins; and (3) the sites
were anatomically separate from the site in question, such as
the acromioclavlcular joint (patient no. 17). Note that the
single FP result (patient no. 13) showed an abnormahty that
did not meet these criteria and therefore was read as a
positive finding.
FDG-PET is one of a variety of scintigraphic techniques
used with varying success to localize melanoma metastases
Recently, carbon- 11 methionine PET has been shown to be
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capable of imaging many foci of melanoma greater than 1.5
cm in diameter. Tnals with radioimmunodetection with
monoclonal antibodies generally result min high specificity,
but relatively poor sensitivity, with the latter reported to
range from 59% to 71% in a recent review.24 Studies with
regional delivery of an iodine-131 antimelanoma monclonal
antibody cocktail have been somewhat more encouraging. 2 5
Increased uptake of (iodine-123)-(S)-IBZM by melanoma
has been descnbed, and the use of gallium-67 citrate with
variable success is well known.2 6 Lymphoscintigraphy is
useful in identifying the draining nodal basin, but cannot
accurately predict involvement. More recently, there has
been interest in ntraoperatlve identification of the first
regional node to take up a vital blue dye or radiocolloid
injected around the site of a cutaneous melanoma pnmary
side. This sentinel node is examined histopathologically at
the time of surgery, with the presence or absence of tumor
expected to hold a high predictive value for involvement of
the remaining nodes in the basin. This technique could
potentially spare the patient a regional node dissection if no
tumor is detected, and is currently the subject of clinical
trials.27 It is likely to be less useful where the draining basin
cannot be confidently identified, unless combined with
preoperative lymphoscmintigraphy.
Other preliminary data suggest that whole-body FDG-
PET is more sensitive in detecting visceral metastases than
current anatomical maging techniques, and also more
cost-effective than the battery of current techniques used in
stagmg.i3 ,28 Based on the 88% accuracy of FDG-PET in
characterizing nodal metastases, it could conceivably be
used as the only additional imaging study in the assessment
of patients with melanoma.
In conclusion, FDG-PET usmg the PET scanners and
scanning algorithm described here is an accurate, although
not infallible, technque for staging of the presence or
absence of regional nodal metastases of melanoma. This
study demonstrates that it has a high positive predictive
value, but that a negative study does not completely exclude
the presence of smcrometastatlc disease.
The optimum strategy for management of patients with an
apparently isolated primary lesion - 1.5 mm has not been
established. There has not been sufficient experience with
FDG-PET to determine its role in this process, or that of
other techniques such as selective lymphadenectomy guided
by patent blue-dye. One approach could involve the use of
attenuation-corrected whole-body PET imaging before con-
sideration of LND. Only if FDG-PET suggests nodal
involvement would a formal node dissection be performed.
FDG-PET shows considerable potential as a tool in the
management of melanoma. The specificity of the method is
high and sensitivity, while also high, will likely nse further
with the continuing improvement m PET scanner resolution.
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